---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-027890"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:49:53.583250+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Bluejay acknowledges NorthStrive's acquisition suggestion, reiterates focus on Symphony platform

## Summary
- Responds to NorthStrive Fund II LP letter proposing acquisition of Phase-1-ready chronic cough therapeutic program.
- Board and management will evaluate the opportunity but emphasize current priorities: Symphony platform, SYMON II study, FDA submission.
- Notes NorthStrive did not identify the potential counterparty; requests additional diligence information if available.
- Reaffirms commitment to fiduciary duties under Delaware law and preserving cash resources.

## SEC filing metadata
- accession: 0001213900-26-027890
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390026027890/0001213900-26-027890-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390026027890/ea0281741-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-027890
- JSON: https://secwatch.observer/filing/0001213900-26-027890.json
- Plain text: https://secwatch.observer/filing/0001213900-26-027890.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.